Back to search

Article

Construction of a Prognostic Model for Extensive-Stage Small Cell Lung Cancer Patients Undergoing Immune Therapy in Real-World Settings and Prediction of Treatment Efficacy Based on Response Status at Different Time Points

2024-03-07

Abstract excerpt

<h4>Background: </h4> and purpose In recent years, with the clinical application of programmed cell death protein-1 (PD-1) represented by serplumab and programmed cell death ligand-1 (PD-L1) represented by durvalumab, immune checkpoint inhibitors (ICIs) have been used in patients with extensive-stage small cell lung cancer (ES-SCLC). clinical applications, immune checkpoint inhibitors (ICIs) have shown significant...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
aa209c76-d908-564c-90e5-3721b4fe32ef
DOI
10.21203/rs.3.rs-4006710/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Construction of a Prognostic Model for Extensive-Stage Small Cell Lung Cancer Patients Undergoing Immune Therapy in Real-World Settings and Prediction of Treatment Efficacy Based on Response Status at Different Time PointsDOI 10.21203/rs.3.rs-4006710/v1
Characteristics and Hematological Indicators Predictors of Immunotherapy Response in Advanced Non-Small Cell Lung CancerSemantic proximity
Comparison of efficacy and safety between PD-1 inhibitors and PD- L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysisSemantic proximity
Real-World Outcomes and Clinical Heterogeneity of First-Line Immunochemotherapy in Extensive-Stage Small-Cell Lung CancerSemantic proximity
Efficacy and Safety of Immuno-based Therapy Versus Standard of Care in Extensive-stage Small-Cell Lung Cancer: An Updated Meta-analysis of Randomized Clinical TrialsSemantic proximity
Real-world Data Analysis of Immunotherapy in Advanced Lung CancerSemantic proximity
A random survival forest-based pathomics signature classifies immunotherapy prognosis and profiles TIME and genomics in ES-SCLC patientsSemantic proximity
Etoposide–Platinum Rechallenge in Small Cell Lung Cancer Worth More Application: A Multicenter Study and Web-Based Predictive ModelSemantic proximity
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 studySemantic proximity
Prediction of 2-Year Mortality in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors Based on a Machine Learning AlgorithmSemantic proximity
Real-world survival outcomes to first-line chemoimmunotherapy and biomarker analysis in extensive-stage small-cell lung cancerSemantic proximity
A novel decision-making tool for first-line treatment selection in metastatic non-small cell lung cancer based on plasma proteome profilingSemantic proximity
The Predictive efficacy of tumor mutational burden for immune Checkpoint Inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trialsSemantic proximity
Select a neighboring publication to make it the new centre.